OncoMatch/Clinical Trials/NCT04793919
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Is NCT04793919 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mylotarg and Arsenic Trioxide for acute promyelocytic leukemia.
Treatment: Mylotarg · Arsenic Trioxide · All-trans retinoic acid — The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: PML fusion with RARA
confirmed by the presence of PML/RARα fusion gene
Prior therapy
Cannot have received: alternative therapy
Exception: APL not initially suspected; ATRA and/or ATO not available
Patients who had received alternative therapy (APL not initially suspected; ATRA and/or ATO not available
Lab requirements
Kidney function
creatinine serum levels >2 times the normal value for age
Liver function
bilirubin serum levels >3 mg/dL, ALT/AST serum levels greater than 5 times the normal values
Cardiac function
significant arrhythmias, EKG abnormalities, L-FEV <50% or LV-FS <28%
Significant liver dysfunction (bilirubin serum levels >3 mg/dL, ALT/AST serum levels greater than 5 times the normal values); Creatinine serum levels >2 times the normal value for age; Significant arrhythmias, EKG abnormalities (*see below), other cardiac contraindications (L-FEV <50% or LV-FS <28%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify